Who is sponsoring NCT05262465?

NCT05262465 is sponsored by guomei.

What condition does NCT05262465 study?

NCT05262465 studies Adult Acute Myeloid Leukemia.

Is NCT05262465 still recruiting?

NCT05262465 is currently status unknown. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT05262465

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Status unknown NA Last updated 2 March 2022

What this trial tests

NA trial testing microtransplantation, HLA-mismatched donor peripheral stem cell infusion in Adult Acute Myeloid Leukemia in 300 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
1 July 2023

1 July 2025

Quick facts

Lead sponsor	guomei
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	1 July 2020
Primary completion	1 July 2023
Estimated completion	1 July 2025
Sites	1 location across China

Drugs / interventions tested

microtransplantation, HLA-mismatched donor peripheral stem cell infusion — full drug profile →
Azacitidine (azacitidine) — full drug profile →
Venetoclax (venetoclax) — full drug profile →

Conditions studied

Adult Acute Myeloid Leukemia — all drugs for Adult Acute Myeloid Leukemia →

Sponsor

guomei

Who can join

Adults 60 to 85, any sex, with Adult Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mitochondria and Acute Leukemia: A Clinician's Perspective.
Iyer P, Jasdanwala SS, Bhatia K, Bhatt S. · · 2024 · cited 6× · PMID 39273651 · DOI 10.3390/ijms25179704

Verify or expand the search:

Other trials of microtransplantation, HLA-mismatched donor peripheral stem cell infusion

Trials testing the same drug.

NCT05095558 — Microtransplantation for Ovarian Cancer · Phase 1, PHASE2 · unknown
NCT04937842 — Microtransplantation for Advanced and Relapsed Solid Tumors · Phase 1, PHASE2 · unknown

Other recruiting trials for Adult Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT06329999 — A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05262465 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by guomei
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05262465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing